MONTREAL, QUEBEC--(MARKET WIRE)--Jun 20, 2006 -- At its Annual General Meeting today, Ambrilia Biopharma Inc. (TSX:AMB.TO - News), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, highlighted the positive Phase Ia results for its lead HIV protease inhibitor PPL-100 and the latest developments in its product portfolio. The meeting was chaired by the Board Chairman, Dr. Max Link, and a progress report was presented by Mr. Hans J. Mader, President and Chief Executive Officer, with financial highlights presented by Mrs. Monique Letourneau, Executive Vice-President, Finance and Chief Financial Officer and a scientific review presented by Dr. Bonabes de Rouge, Senior Executive Vice-President and Chief Scientific Officer.
